Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranolazine extended release - Gilead Sciences

Next Previous
Drug Profile

Ranolazine extended release - Gilead Sciences

Alternative Names: CORZYNA; CVT 303; CVT 3041; KEG 1295; RAN D; Ran4; Ranexa; Ranolazine hydrochloride; RS 43285; RS 43285-003; RS 43285-193; ™CORZYNA™

Latest Information Update: 07 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntex Pharmaceuticals International
  • Developer CV Therapeutics; Gilead Sciences; Kissei Pharmaceutical; KYE Pharmaceuticals; Menarini; North Shore-Long Island Jewish Health System; Ohio State University; University of Rochester
  • Class Acetanilides; Anti-ischaemics; Antiarrhythmics; Antihyperglycaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Pyruvate dehydrogenase stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus
  • Phase II Aortic valve stenosis; Diastolic heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia; Myotonic dystrophy
  • Discontinued Intermittent claudication; Ventricular arrhythmias

Most Recent Events

  • 04 May 2021 Launched for Angina pectoris (Adjunctive treatment) in Canada (PO)
  • 28 Jan 2021 A.Menarini Asia-Pacific Holdings completes a phase I trial in healthy volunteers in South Korea (NCT02817932)
  • 31 Dec 2020 Gilead Sciences has patent protection for ranolazine extended release the European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top